Announcement no. 5/2019
Comment on market rumours
Coloplast confirms that the company is conducting an unconditional strategic review of its Interventional Urology division. Further information will be communicated to the market as it becomes available.
Kind regards,
Coloplast A/S
Ellen Bjurgert, Vice President, Investor Relations
For more information, please contact:
Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111
Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 / 4911 3376
E-mail dkebj@coloplast.com
Rasmus Sørensen
Senior Manager, Investor Relations
Tel. +45 4911 1800 / 4911 1786
E-mail dkraso@coloplast.com
Press and the media
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
Tel. +45 4911 2607
E-mail dklina@coloplast.com
Website
www.coloplast.com
Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebæk
Denmark
Business reg. (CVR) no. 69749917
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2019-6 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.
Our business includes Ostomy Care, Interventional Urology, Continence Care and Wound and Skin Care. We operate globally and employ about 12,000 people.
Attachment
